Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
McKinsey
Moodys
Harvard Business School
Merck

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR OXYCODONE AND ASPIRIN (HALF-STRENGTH)


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Oxycodone And Aspirin (half-strength)

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00771758 ↗ Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis Completed Grünenthal GmbH Phase 3 2008-09-01 The purpose of this study is to determine the effectiveness and safety of tapentadol immediate release (IR) as compared with placebo and oxycodone IR in patients with acute pain caused by vertebral compression fractures (VCF) associated with assumed osteoporosis for whom treatment with oral opioid analgesics is appropriate.
NCT00771758 ↗ Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis Completed Ortho-McNeil Janssen Scientific Affairs, LLC Phase 3 2008-09-01 The purpose of this study is to determine the effectiveness and safety of tapentadol immediate release (IR) as compared with placebo and oxycodone IR in patients with acute pain caused by vertebral compression fractures (VCF) associated with assumed osteoporosis for whom treatment with oral opioid analgesics is appropriate.
NCT00814580 ↗ Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery Completed Grünenthal GmbH Phase 3 2008-12-01 The purpose of this study is to evaluate how tapentadol immediate release (IR) and oxycodone IR treat moderate to severe post-operative pain after elective arthroscopic shoulder surgery.
NCT00814580 ↗ Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery Completed Ortho-McNeil Janssen Scientific Affairs, LLC Phase 3 2008-12-01 The purpose of this study is to evaluate how tapentadol immediate release (IR) and oxycodone IR treat moderate to severe post-operative pain after elective arthroscopic shoulder surgery.
NCT01080677 ↗ Caffeine/Propranolol Intervention for Acute Migraine Completed Stanford University Phase 2 2007-01-01 This is a research study to assess the safety of caffeine/propranolol at different dose levels. We want to find out what effects, good and/or bad, it has on patients and their migraines.
NCT02160301 ↗ Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients Withdrawn University of North Carolina, Chapel Hill Phase 4 2017-11-01 The study is a prospective, randomized, open-label comparison of a multimodal regimen and a standard, narcotic-based regimen for postoperative pain control in patients undergoing surgery for an operatively indicated, isolated extremity fracture. The investigators will be measuring pain levels, narcotic use, patient satisfaction, patient reported function, adverse events and fracture union. The investigators hypothesize that this multimodal regimen will lead to improved pain, less narcotic use and improved satisfaction as compared to the standard regimen.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Oxycodone And Aspirin (half-strength)

Condition Name

Condition Name for Oxycodone And Aspirin (half-strength)
Intervention Trials
Polycythemia Vera 1
Post Operative Pain Control 1
Postoperative Pain 1
Tranexamic Acid Adverse Reaction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Oxycodone And Aspirin (half-strength)
Intervention Trials
Pain, Postoperative 2
Acute Pain 1
Polycythemia 1
Migraine Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Oxycodone And Aspirin (half-strength)

Trials by Country

Trials by Country for Oxycodone And Aspirin (half-strength)
Location Trials
United States 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Oxycodone And Aspirin (half-strength)
Location Trials
North Carolina 3
New York 3
Arizona 2
California 2
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Oxycodone And Aspirin (half-strength)

Clinical Trial Phase

Clinical Trial Phase for Oxycodone And Aspirin (half-strength)
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Oxycodone And Aspirin (half-strength)
Clinical Trial Phase Trials
Completed 4
Unknown status 1
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Oxycodone And Aspirin (half-strength)

Sponsor Name

Sponsor Name for Oxycodone And Aspirin (half-strength)
Sponsor Trials
Grünenthal GmbH 2
Ortho-McNeil Janssen Scientific Affairs, LLC 2
Stanford University 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Oxycodone And Aspirin (half-strength)
Sponsor Trials
Industry 6
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Boehringer Ingelheim
Moodys
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.